12 related articles for article (PubMed ID: 38723281)
1. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells.
Kumar H; Mazumder S; Sharma N; Chakravarti S; Long MD; Meurice N; Petit J; Liu S; Chesi M; Sanyal S; Stewart AK; Kumar S; Bergsagel L; Rajkumar SV; Baughn LB; Van Ness BG; Mitra AK
Front Oncol; 2022; 12():842200. PubMed ID: 35646666
[TBL] [Abstract][Full Text] [Related]
2. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S; Lee H; Welsh SJ; Riggs DL; Stong N; Flynt E; Thakurta A; Keats JJ; Lonial S; Bergsagel PL; Boise LH; Bahlis NJ
Blood Cancer Discov; 2024 Jan; 5(1):56-73. PubMed ID: 37934799
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy.
Colley A; Brauns T; Sluder AE; Poznansky MC; Gemechu Y
Trends Mol Med; 2024 May; ():. PubMed ID: 38821771
[TBL] [Abstract][Full Text] [Related]
4. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
5. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Welsh SJ; Barwick BG; Meermeier EW; Riggs DL; Shi CX; Zhu YX; Sharik ME; Du MT; Abrego Rocha LD; Garbitt VM; Stein CK; Petit JL; Meurice N; Tafoya Alvarado Y; Fonseca R; Todd KT; Brown S; Hammond ZJ; Cuc NH; Wittenberg C; Herzog C; Roschke AV; Demchenko YN; Chen WD; Li P; Liao W; Leonard WJ; Lonial S; Bahlis NJ; Neri P; Boise LH; Chesi M; Bergsagel PL
Blood Cancer Discov; 2024 Jan; 5(1):34-55. PubMed ID: 37767768
[TBL] [Abstract][Full Text] [Related]
7. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
8. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
9. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2024 May; ():. PubMed ID: 38723281
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
